| Cellular resistance to anthracyclines D Nielsen, C Maare, T Skovsgaard General Pharmacology: The Vascular System 27 (2), 251-255, 1996 | 202 | 1996 |
| Cancer of the external auditory canal and middle ear in Denmark from 1992 to 2001 AR Madsen, MG Gundgaard, CM Hoff, C Maare, P Holmboe, M Knap, ... Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2008 | 90 | 2008 |
| Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation D Nielsen, C Maare, J Eriksen, T Litman, T Skovsgaard International Journal of Radiation Oncology* Biology* Physics 51 (4), 1050-1057, 2001 | 51 | 2001 |
| Cellular resistance to cancer chemotherapy T Skovsgaard, D Nielsen, C Maare, K Wassermann International review of cytology 156, 77-157, 1994 | 43 | 1994 |
| NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy CR Hansen, J Friborg, K Jensen, E Samsøe, L Johnsen, R Zukauskaite, ... Acta Oncologica 58 (10), 1410-1415, 2019 | 33 | 2019 |
| Dosimetric and geometric evaluation of the use of deformable image registration in adaptive intensity-modulated radiotherapy for head-and-neck cancer RB Eiland, C Maare, D Sjöström, E Samsøe, CF Behrens Journal of radiation research 55 (5), 1002-1008, 2014 | 28 | 2014 |
| Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil D Nielsen, C Maare, T Skovsgaard Biochemical pharmacology 50 (4), 443-450, 1995 | 26 | 1995 |
| Evaluation of the EGFR-inhibitor zalutumumab given with primary curative (Chemo) radiation therapy to patients with squamous cell carcinoma of the head and neck: results of the … JG Eriksen, C Maare, J Johansen, H Primdahl, JF Evensen, ... International Journal of Radiation Oncology, Biology, Physics 88 (2), 465, 2014 | 24 | 2014 |
| Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein: Influence of verapamil D Nielsen, C Maare, T Skovsgaard Biochemical pharmacology 47 (12), 2125-2135, 1994 | 20 | 1994 |
| Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone D Nielsen, J Eriksen, C Maare, T Litman, E Kjærsgaard, T Plesner, ... Biochemical pharmacology 60 (3), 363-370, 2000 | 14 | 2000 |
| OC-009: Update of the randomised phase III trial DAHANCA 19: Primary C-RT or RT and zalutumumab for squamous cell carcinomas of head and neck JG Eriksen, C Maare, J Johansen, H Primdahl, J Evensen, CA Kristensen, ... Radiotherapy and Oncology, 10, 2015 | 13 | 2015 |
| P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin D Nielsen, J Eriksen, C Maare, AH Jakobsen, T Skovsgaard British journal of cancer 78 (9), 1175-1180, 1998 | 13 | 1998 |
| The relationship between resistance, P-glycoprotein content, and steady state accumulation in five series of Ehrlich ascites tumor cell lines selected for resistance to … D Nielsen, C Maare, F Poulsen, ST Lauridsen, T Skovsgaard Cell Pharmacol 1, 127-135, 1994 | 11 | 1994 |
| DAHANCA 19: first results of a randomized phase III study of the importance of the EGFR-inhibitor zalutumumab for the outcome of primary curative radiotherapy for squamous cell … JG Eriksen, C Maare, J Johansen, H Primdahl, J Evensen, CA Kristensen, ... | 10 | 2013 |
| Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from … L Brøndum, J Alsner, BS Sørensen, C Maare, J Johansen, H Primdahl, ... Acta Oncologica 57 (9), 1159-1164, 2018 | 9 | 2018 |
| Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide D Nielsen, C Maare, J Eriksen, T Litman, E Friche, T Skovsgaard Biochemical pharmacology 60 (3), 353-361, 2000 | 7 | 2000 |
| Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer J Friborg, K Jensen, JG Eriksen, E Samsøe, C Maare, M Farhadi, P Sibolt, ... Radiotherapy and Oncology, 109958, 2023 | 6 | 2023 |
| DAHANCA 19: A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas JG Eriksen, C Maare, H Primdahl, J Evensen, CA Kristensen, ... | 6 | 2014 |
| Split-filter dual energy computed tomography radiotherapy: From calibration to image guidance J Edmund, MF Rønjom, M van Overeem Felter, C Maare, AMJ Dam, ... Physics and imaging in radiation oncology 28, 100495, 2023 | 5 | 2023 |
| 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT+/-zalutumumab in HNSCC JG Eriksen, C Maare, J Johansen, H Primdahl, J Evensen, CA Kristensen, ... Radiotherapy & Oncology 127 (Supplement 1), S137-S138, 2018 | 5 | 2018 |
